GILD GILEAD SCIENCES, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 882095 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.5%
TTM net income YoY-147.6%
TTM EPS YoY-148.5%
Revenue 3-yr CAGR4.2%
Net income 3-yr CAGR—
Margins
Gross margin79.9%
Operating margin-7.6%
Net margin-12.5%
FCF margin44.5%
EBITDA margin-6.3%
Returns
ROE-22.3%
ROA-7.0%
ROIC (approx.)-5.2%
Asset turnover0.56x
Leverage & solvency
Liabilities / assets74.8%
Debt / equity2.01x
Current ratio1.38x
Interest coverage-2.34x
Cash quality & payout
Operating cash flow / net income-3.75x
Accruals ratio-33.4%
Payout ratio—
Capex / revenue2.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $29.44B | $28.75B | $27.12B | $27.28B | $27.30B |
| Cost of revenue | $6.23B | $6.25B | $6.50B | $5.66B | $6.60B |
| Gross profit | $23.21B | $22.50B | $20.62B | $21.62B | $20.70B |
| R&D expense | $5.80B | $5.91B | $5.72B | $4.98B | $4.60B |
| SG&A expense | $5.77B | $6.09B | $6.09B | $5.67B | $5.25B |
| Operating income | $10.02B | $1.66B | $7.61B | $7.33B | $9.92B |
| Interest expense | $1.02B | $977.00M | $944.00M | $935.00M | $1.00B |
| Pretax income | $9.80B | $690.00M | $6.86B | $5.81B | $8.28B |
| Income tax | $1.29B | $211.00M | $1.25B | $1.25B | $2.08B |
| Net income | $8.51B | $480.00M | $5.67B | $4.59B | $6.22B |
| EBITDA | $10.39B | $2.04B | $7.96B | $7.65B | $10.25B |
| EPS (basic) | 6.84 | 0.38 | 4.54 | 3.66 | 4.96 |
| EPS (diluted) | 6.78 | 0.38 | 4.50 | 3.64 | 4.93 |
| Dividends declared per share | 3.16 | 3.08 | 3.00 | 2.92 | 2.84 |
| Weighted avg. shares (diluted) | 1.25B | 1.25B | 1.26B | 1.26B | 1.26B |
| Balance sheet | |||||
| Cash & equivalents | $7.56B | $9.99B | $6.08B | $5.41B | $5.34B |
| Short-term investments | $68.00M | $0 | $1.18B | $973.00M | $1.18B |
| Receivables | $4.91B | $4.42B | $4.66B | $4.78B | $4.49B |
| Inventory | $1.77B | $1.71B | $1.79B | $1.51B | $1.62B |
| Current assets | $18.34B | $19.17B | $16.09B | $14.44B | $14.77B |
| PP&E, net | $5.61B | $5.41B | $5.32B | $5.47B | $5.12B |
| Goodwill | $8.31B | $8.31B | $8.31B | $8.31B | $8.33B |
| Intangibles | $16.98B | $19.95B | $26.45B | $28.89B | $33.45B |
| Total assets | $59.02B | $58.99B | $62.12B | $63.17B | $67.95B |
| Current liabilities | $11.81B | $12.00B | $11.28B | $11.24B | $11.61B |
| Short-term debt | $2.81B | $1.81B | $1.80B | $2.27B | $1.52B |
| Long-term debt | $22.13B | $24.90B | $23.19B | $22.96B | $25.18B |
| Total debt | $24.94B | $26.71B | $24.99B | $25.23B | $26.70B |
| Total liabilities | $36.41B | $39.75B | $39.38B | $41.96B | $46.89B |
| Shareholders' equity | $22.70B | $19.33B | $22.83B | $21.24B | $21.07B |
| Net debt | $17.37B | $16.72B | $18.90B | $19.82B | $21.36B |
| Shares outstanding | 1.24B | 1.25B | 1.25B | 1.25B | 1.25B |
| Cash flow statement | |||||
| Operating cash flow | $10.02B | $10.83B | $8.01B | $9.07B | $11.38B |
| Capital expenditure | $563.00M | $523.00M | $585.00M | $728.00M | $579.00M |
| Free cash flow | $9.46B | $10.30B | $7.42B | $8.34B | $10.80B |
| Investing cash flow | -$4.79B | -$3.45B | -$2.27B | -$2.47B | -$3.13B |
| Financing cash flow | -$7.75B | -$3.43B | -$5.12B | -$6.47B | -$8.88B |
| Depreciation & amortization | $370.00M | $381.00M | $354.00M | $323.00M | $329.00M |
| Stock-based compensation | $894.00M | $835.00M | $766.00M | $637.00M | $635.00M |
| Dividends paid | $4.00B | $3.92B | $3.81B | $3.71B | $3.60B |
| Share buybacks | $1.92B | $1.15B | $1.00B | $1.40B | $546.00M |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.